2017. EXTEND *more results

RCT/ ADA/ CD / Induct/Maintain

Randomized double-blind controlled trial. Active ileocolonic CD patients received Adalimumab induction then randomised to: placebo vs 40mg Ada eow.

<u>Primary endpoint</u>: changes in endoscopy w12 and w52 <u>Secondary endpoints</u>: CDEIS surface by ileocolonic segment changes; SES-CD; histology changes.


Results:


- No differences at w12 comparing induction+pbo vs induction+ADA but differences found in w52.
- w52: healing was more common in colon 28.3% vs ileum 21.2%
- Favourable shifts w52 in ulcer size and surfaces more pronounced in rectum, sigmoid/left colon and transverse vs the right colon and ileum.

Conclusions:

Differing propensities of the ileocolonic segments to heal endoscopically during ADA treatment.

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Mod-Severely Active CD: Results from the EXTEND Trial





Original EXTEND trial was published in 2012

Reinisch W et al. J Crohn Colitis 2017, 425-434

H